Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF. Derosa G, et al. Among authors: ragonesi pd. J Clin Pharm Ther. 2006 Aug;31(4):375-83. doi: 10.1111/j.1365-2710.2006.00756.x. J Clin Pharm Ther. 2006. PMID: 16882108 Clinical Trial.
Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.
Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Cicero AF. Derosa G, et al. Among authors: ragonesi pd. J Int Med Res. 2006 Sep-Oct;34(5):545-55. doi: 10.1177/147323000603400513. J Int Med Res. 2006. PMID: 17133785 Free article. Clinical Trial.
Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF. Derosa G, et al. Among authors: ragonesi pd. J Clin Pharm Ther. 2009 Jun;34(3):267-76. doi: 10.1111/j.1365-2710.2008.01004.x. J Clin Pharm Ther. 2009. PMID: 19650249 Clinical Trial.
Exenatide versus glibenclamide in patients with diabetes.
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF. Derosa G, et al. Among authors: ragonesi pd. Diabetes Technol Ther. 2010 Mar;12(3):233-40. doi: 10.1089/dia.2009.0141. Diabetes Technol Ther. 2010. PMID: 20151774 Clinical Trial.
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN. Derosa G, et al. Among authors: ragonesi pd. Clin Ther. 2004 May;26(5):744-54. doi: 10.1016/s0149-2918(04)90074-4. Clin Ther. 2004. PMID: 15220018 Clinical Trial.
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R. Derosa G, et al. Among authors: ragonesi pd. Diabetes Res Clin Pract. 2005 Jul;69(1):5-13. doi: 10.1016/j.diabres.2004.10.007. Epub 2004 Dec 29. Diabetes Res Clin Pract. 2005. PMID: 15955382 Clinical Trial.
26 results